Skip to content
MedsAcross

Molecule

Flortaucipir f-18

Available on request
Presentations
1
Brands
1
Manufacturers
1
Available from stock
0

Flortaucipir f-18 is a prescription medicine indicated with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment. MedsAcross supplies Flortaucipir f-18 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

US FDA first approval
28 May 2020
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intravenous
Dosage forms
Injection
Identifiers
UNII T1JP1KYU9OCAS 1522051-90-6DrugBank DB14914Q21936669

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). TAUVID is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). Limitations of Use TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

Source: US FDA prescribing information

How it works

Flortaucipir F 18 binds to aggregated tau protein. In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD. In vitro, flortaucipir F 18 binds to paired helical filament (PHF) tau purified from brain homogenates of donors with AD. The dissociation constant (Kd) of flortaucipir F 18 binding to PHFs is 0.57 nM. In vivo, flortaucipir F 18 is differentially retained in neocortical areas that contain aggregated tau. In vitro, tritiated flortaucipir has been reported to bind with low nanomolar affinity to monoamine oxidase-A and monoamine oxidase-B, which could contribute to off target binding.

Source: US FDA prescribing information

Dosing overview

Recommended dose is 370 MBq (10 mCi), administered as a bolus intravenous injection. Initiate imaging approximately 80 minutes after drug administration. See full prescribing information for additional preparation, administration, imaging, and radiation dosimetry information.

Source: US FDA prescribing information

Warnings and precautions

Risk of Misdiagnosis in Patients Evaluated for Alzheimer's disease: Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan. Risk of Chronic Traumatic Encephalopathy Misdiagnosis: The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Radiation Risk: Ensure safe drug handling to protect patients and health care workers from unintentional radiation exposure.

Source: US FDA prescribing information

Side effects

Most common adverse reactions (frequency ≥ 0.5%) were headache, injection site pain, and increased blood pressure.

Source: US FDA prescribing information

Storage

Storage Store TAUVID at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store TAUVID upright in a shielding container.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

1 presentations of Flortaucipir f-18, sorted by availability.

MedicineManufacturerRegisterAvailability
Tauvid 100 mCi/mL injectionIntravenousEli LillyUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Tauvid

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 28 May 2020Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Flortaucipir f-18 available for export from India?

Yes, on request. MedsAcross lists 1 presentations of Flortaucipir f-18 and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Flortaucipir f-18 have?

The catalogue lists 1 brand names for Flortaucipir f-18, including Tauvid.

Is Flortaucipir f-18 approved by the US FDA?

Yes. The US FDA first approved Flortaucipir f-18 on 28 May 2020, according to Drugs@FDA.

Does Flortaucipir f-18 need cold chain shipping?

No listed presentation of Flortaucipir f-18 is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

References

  1. TAUVID prescribing information (Eli Lilly). U.S. National Library of Medicine, DailyMed. Retrieved 30 December 2025

Request Flortaucipir f-18 for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quoteRead the import guides